Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Biomed Chromatogr ; 34(1): e4699, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31524294

RESUMEN

In this study, we developed and validated two reliable high-performance liquid chromatography (HPLC) methods for the qualitative detection of six oral ß-lactams, which are commonly used in pediatric patients with acute respiratory infections (ARIs). Two distinct reverse-phase chromatographic separations of six ß-lactams were obtained. Four ß-lactams (cefadroxil, cephalexin, cefaclor and cefixime) in urine were separated using a gradient program with a mobile phase consisting of K2 HPO4 buffer (20 mm, pH 2.8) and acetonitrile on a LichroCART 250 × 4.6 mm, Purospher STAR C18 end-capped (5 µm) column. Two remained ß-lactams (amoxicillin and cefuroxime) were analyzed using a gradient elution with the mobile phase containing K2 HPO4 buffer (20 mm, pH 3.0) and acetonitrile on a LichroCart® Purospher Star C8 end-capped column (5 µm, 125 × 4.6 mm). Good linearity within the range of 0.3-30 µg/ml for cefadroxil, cephalexin, cefaclor and cefixime, and 0.2-20 µg/ml for amoxicillin and cefuroxime, was attained. The precisions were <14%. The accuracies ranged from 85.87 to 102.8%. The two validated methods were then applied to determine these six antibiotics in 553 urine samples of pediatric patients with ARIs. As a result, 32.2% were positive with one or more of six tested ß-lactams. Cefixime was the most commonly detected agent, accounting for 9.8% of enrolled patients.


Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Infecciones del Sistema Respiratorio/tratamiento farmacológico , beta-Lactamas/orina , Enfermedad Aguda , Adolescente , Niño , Preescolar , Cromatografía de Fase Inversa/métodos , Humanos , Lactante , Recién Nacido , Límite de Detección , Modelos Lineales , Uso Excesivo de Medicamentos Recetados , Reproducibilidad de los Resultados , beta-Lactamas/uso terapéutico
2.
Blood Purif ; 44 Suppl 1: 46-51, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28869938

RESUMEN

We report a case of calcium pyrophosphate dihydrate deposition disease (CPDD) involving a patient on maintenance hemodialysis (MHD). The 32-year-old man presented in August 2016 with a complaint of left shoulder swelling of 8 months' duration with no trauma or fever. He was diagnosed with nephrotic syndrome in 1998, which progressed to ESRD. He commenced MHD in 2012. Examination at our hospital revealed a soft nontender swelling of the left shoulder. Blood biochemistry showed elevated serum urate, phosphate, ß2 microglobulin, and parathyroid hormone. Imaging revealed joint effusion and dense heterogenous deposition. Aspirate analysis showed urate crystals 3+, and culture yielded no growth. Following rheumatology review, the working diagnosis was periarticular tissue tuberculosis, after excluding pseudogout and amyloidosis. Following 1 month of colchicine and allopurinol, synovial fluid microscopy showed CPDD crystals. Symptoms gradually resolved over the course of 6 months. In this rare case, a diagnosis of CPDD was made with a multidisciplinary approach that included imaging and biochemical investigations.


Asunto(s)
Alopurinol/administración & dosificación , Enfermedades Óseas Metabólicas , Condrocalcinosis , Colchicina/administración & dosificación , Fallo Renal Crónico , Síndrome Nefrótico , Diálisis Renal/efectos adversos , Adulto , Enfermedades Óseas Metabólicas/sangre , Enfermedades Óseas Metabólicas/tratamiento farmacológico , Enfermedades Óseas Metabólicas/etiología , Condrocalcinosis/sangre , Condrocalcinosis/tratamiento farmacológico , Condrocalcinosis/etiología , Humanos , Fallo Renal Crónico/sangre , Fallo Renal Crónico/terapia , Masculino , Síndrome Nefrótico/sangre , Síndrome Nefrótico/terapia , Vietnam
3.
BMC Infect Dis ; 16: 144, 2016 Apr 02.
Artículo en Inglés | MEDLINE | ID: mdl-27039088

RESUMEN

BACKGROUND: Among the various forms of TB, tuberculous meningitis (TBM) is the most severe, with about 30% mortality and 50% of survivors left with neurological sequelae. Children suffer more frequently from TBM than adults and outcomes are often poor due to difficulties in making the diagnosis and uncertainty regarding the best anti-tuberculosis drug regimen. The aim of this prospective study was to describe the pharmacokinetics of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of children with tuberculous meningitis treated with the standard TBM regimen. METHODS: We performed a prospective observational study of 100 consecutively treated children (≤ 15 years of age) with tuberculous meningitis in Ho Chi Minh City, Vietnam. Children were treated according to the 2006 WHO recommended pediatric treatment regimen consisting of isoniazid (5 mg/kg), rifampicin (10 mg/kg) and ethambutol (15 mg/kg) for 8 months, with the addition of pyrazinamide (25 mg/kg) for the first 3 months and streptomycin (15 mg/kg) for the first 2 months. Pyrazinamide, isoniazid and rifampicin concentrations were measured in plasma at day 14 and in cerebrospinal fluid (CSF) at 1 month by HPLC-UV. A naïve-pooled non-compartmental data analysis was used to describe the pharmacokinetic properties of drugs in the two-age groups of children ≤ 4 years or > 4 years of age. RESULTS: Younger children, when compared to older children, presented a higher body weight-normalized clearance and volume of distribution, and lower median total plasma exposures for the three studied drugs with -14%, -22% and -16% for Pyrazinamide, Isoniazid and Rifampicin, respectively. In CSF, individual concentrations of isoniazid and pyrazinamide were comparable to that in plasma in both age groups; but rifampicin concentrations were lower than the minimum inhibitory concentration of susceptible bacteria in all but two children. CONCLUSIONS: There is an age-dependent variation in the plasma and cerebrospinal fluid pharmacokinetics of rifampicin, isoniazid and pyrazinamide. The safety and efficacy of higher doses of rifampicin should be investigated for the treatment of childhood tuberculous meningitis.


Asunto(s)
Antituberculosos/uso terapéutico , Isoniazida/uso terapéutico , Pirazinamida/uso terapéutico , Rifampin/uso terapéutico , Tuberculosis Meníngea/diagnóstico , Adolescente , Antituberculosos/farmacocinética , Arilamina N-Acetiltransferasa/genética , Pueblo Asiatico , Niño , Preescolar , Femenino , Genotipo , Semivida , Humanos , Lactante , Isoniazida/sangre , Isoniazida/líquido cefalorraquídeo , Masculino , Estudios Prospectivos , Pirazinamida/sangre , Pirazinamida/líquido cefalorraquídeo , Rifampin/sangre , Rifampin/líquido cefalorraquídeo , Tuberculosis Meníngea/tratamiento farmacológico , Vietnam
4.
PLoS One ; 15(11): e0241760, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33147269

RESUMEN

BACKGROUND AND OBJECTIVES: Treatment guidelines do not recommend antibiotic use for acute respiratory infections (ARI), except for streptococcal pharyngitis/tonsillitis and pneumonia. However, antibiotics are prescribed frequently for children with ARI, often in absence of evidence for bacterial infection. The objectives of this study were 1) to assess the appropriateness of antibiotic prescriptions for mild ARI in paediatric outpatients in relation to available guidelines and detected pathogens, 2) to assess antibiotic use on presentation using questionnaires and detection in urine 3) to assess the carriage rates and proportions of resistant intestinal Enterobacteriaceae before, during and after consultation. MATERIALS AND METHODS: Patients were prospectively enrolled in Children's Hospital 1, Ho Chi Minh City, Vietnam and diagnoses, prescribed therapy and outcome were recorded on first visit and on follow-up after 7 days. Respiratory bacterial and viral pathogens were detected using molecular assays. Antibiotic use before presentation was assessed using questionnaires and urine HPLC. The impact of antibiotic usage on intestinal Enterobacteriaceae was assessed with semi-quantitative culture on agar with and without antibiotics on presentation and after 7 and 28 days. RESULTS: A total of 563 patients were enrolled between February 2009 and February 2010. Antibiotics were prescribed for all except 2 of 563 patients. The majority were 2nd and 3rd generation oral cephalosporins and amoxicillin with or without clavulanic acid. Respiratory viruses were detected in respiratory specimens of 72.5% of patients. Antibiotic use was considered inappropriate in 90.1% and 67.5%, based on guidelines and detected pathogens, respectively. On presentation parents reported antibiotic use for 22% of patients, 41% of parents did not know and 37% denied antibiotic use. Among these three groups, six commonly used antibiotics were detected with HPLC in patients' urine in 49%, 40% and 14%, respectively. Temporary selection of 3rd generation cephalosporin resistant intestinal Enterobacteriaceae during antibiotic use was observed, with co-selection of resistance to aminoglycosides and fluoroquinolones. CONCLUSIONS: We report overuse and overprescription of antibiotics for uncomplicated ARI with selection of resistant intestinal Enterobacteriaceae, posing a risk for community transmission and persistence in a setting of a highly granular healthcare system and unrestricted access to antibiotics through private pharmacies. REGISTRATION: This study was registered at the International Standard Randomised Controlled Trials Number registry under number ISRCTN32862422: http://www.isrctn.com/ISRCTN32862422.


Asunto(s)
Antibacterianos/farmacología , Enterobacteriaceae/efectos de los fármacos , Microbioma Gastrointestinal/efectos de los fármacos , Infecciones del Sistema Respiratorio/diagnóstico , Amoxicilina/farmacología , Amoxicilina/uso terapéutico , Amoxicilina/orina , Antibacterianos/uso terapéutico , Antibacterianos/orina , Cefalosporinas/farmacología , Cefalosporinas/uso terapéutico , Cefalosporinas/orina , Niño , Preescolar , Cromatografía Líquida de Alta Presión , Prescripciones de Medicamentos/estadística & datos numéricos , Farmacorresistencia Bacteriana , Enterobacteriaceae/crecimiento & desarrollo , Enterobacteriaceae/aislamiento & purificación , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Pacientes Ambulatorios , Estudios Prospectivos , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/patología , Índice de Severidad de la Enfermedad , Vietnam
5.
J Chromatogr B Analyt Technol Biomed Life Sci ; 1061-1062: 256-262, 2017 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-28756357

RESUMEN

An accurate and reliable high-performance liquid chromatography with time-programmed fluorescence detection was developed and validated to measure levofloxacin in human plasma and cerebrospinal fluid (CSF). After solid phase extraction process using Evolute® ABN 96 fixed well plate; levofloxacin and internal standard-enoxacin were separated using a mobile phase consisting of phosphate buffer 10mM with 0.025% triethylamine pH 3.0 - acetonitrile (88:12, v/v) on a Purosphere RP-8e column (5µm, 125×4.0mm) at a flow rate of 1.2mL/min at 35°C. The excitation/emission wavelengths were set to 269/400nm and 294/500nm, for enoxacin and levofloxacin, respectively. The method was linear over the concentration range of 0.02 to 20.0µg/mL with a limit of detection of 0.01µg/mL. The relative standard deviation of intra-assay and inter-assay precision for levofloxacin at four quality controls concentrations (0.02, 0.06, 3.0 and 15.0µg/mL) were less than 7% and the accuracies ranged from 96.75% to 101.9% in plasma, and from 93.00% to 98.67% in CSF. The validated method was successfully applied to quantify levofloxacin in a considerable quantity of plasma (826) and CSF (477) samples collected from 232 tuberculous meningitis patients, and the preliminary intensive pharmacokinetics analysis from 14 tuberculous meningitis patients in Vietnam is described in this paper.


Asunto(s)
Antibacterianos/sangre , Antibacterianos/líquido cefalorraquídeo , Cromatografía Líquida de Alta Presión/métodos , Levofloxacino/sangre , Levofloxacino/líquido cefalorraquídeo , Tuberculosis Meníngea/tratamiento farmacológico , Adulto , Antibacterianos/farmacocinética , Estabilidad de Medicamentos , Enoxacino , Humanos , Levofloxacino/farmacocinética , Límite de Detección , Modelos Lineales , Reproducibilidad de los Resultados , Extracción en Fase Sólida , Espectrometría de Fluorescencia
6.
PLoS One ; 9(7): e102047, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25004128

RESUMEN

SETTING: In most developing countries, paediatric tuberculosis is treated with split tablets leading to potential inaccuracy in the dose delivery and drug exposure. There is no data on the quality of first-line drugs content in split fixed-dose combination tablets. OBJECTIVE: To determine Isoniazid, Pyrazinamide and Rifampicin content uniformity in split FDC tablets used in the treatment of childhood tuberculosis. DESIGN: Drug contents of 15 whole tablets, 30 half tablets and 36 third tablets were analysed by high performance liquid chromatography. The content uniformity was assessed by comparing drug content measured in split portions with their expected amounts and the quality of split portions was assessed applying qualitative specifications for whole tablets. RESULTS: All whole tablets measurements fell into the USP proxy for the three drugs. But a significant number of half and third portions was found outside the tolerated variation range and the split formulation failed the requirements for content uniformity. To correct for the inaccuracy of splitting the tablets into equal portions, a weight-adjustment strategy was used but this did not improve the findings. CONCLUSION: In split tablets the content of the three drugs is non-uniform and exceeded the USP recommendations. There is an absolute need to make child-friendly formulations available for the treatment of childhood tuberculosis.


Asunto(s)
Isoniazida/análisis , Pirazinamida/análisis , Rifampin/análisis , Química Farmacéutica/normas , Combinación de Medicamentos , Humanos , Isoniazida/uso terapéutico , Pirazinamida/uso terapéutico , Control de Calidad , Rifampin/uso terapéutico , Comprimidos , Tuberculosis Pulmonar/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA